Clinical Trials Browser

Phase 3 × Denosumab × 1 year × Clear all

NCT02051218 2025-12-30

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Phase 3 Active not recruiting

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04711109 2025-04-02

BRCA-P

Phase 3 Active not recruiting

Breast Diseases, Breast Neoplasms, Neoplasms